<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00584402</url>
  </required_header>
  <id_info>
    <org_study_id>200715241</org_study_id>
    <nct_id>NCT00584402</nct_id>
  </id_info>
  <brief_title>Contrast Sonography for Evaluation of Liver Tumors Prior to Radiofrequency Ablation</brief_title>
  <official_title>Contrast Sonography for Evaluation of Liver Tumors Prior to Radiofrequency Ablation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Davis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Davis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy of the Definity (perflutren lipid
      microsphere Injectable Suspension) ultrasound contrast agent in identifying small tumors
      (hepatomas &amp; metastases) within the liver.

      Primary objective: To estimate the increase in conspicuity of small intrahepatic tumors with
      contrast-enhanced sonography

      Secondary Objectives: To estimate the effect of tumor type, size, location and depth on the
      conspicuity of small tumors on contrast-enhanced sonography
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An estimated 75 patients (age 18 years of age or older) will be enrolled from the population
      of patients who present for ultrasound-guided radiofrequency ablation (RFA) of CT or
      MRI-confirmed multiple primary hepatocellular carcinoma (HCC) or metastatic carcinoma, with
      at least one of the tumors being ≤ 1.5 cm in diameter.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of Tumors With Increased Echogenicity (Brightness) Following Contrast-enhanced Sonography</measure>
    <time_frame>15 min</time_frame>
    <description>After the systemic iv injection of ultrasound contrast, the real time ultrasound images are visually evaluated, and small intrahepatic tumors are detected on the images. The images pre-contrast and post contrast are compared visually. One tumor per participant was analyzed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With an Increase in Echogenicity (Brightness) of Small Intrahepatic Tumors Following Contrast-enhanced Sonography Based on Tumor Type, Size, Location and Depth</measure>
    <time_frame>15 min</time_frame>
    <description>Visual estimation of the the effect of tumor type, size, location and depth on the conspicuity of small tumors on contrast-enhanced sonography using prior assessment or pathology for tumor type</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Liver Neoplasms</condition>
  <arm_group>
    <arm_group_label>Contrast sonography</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Contrast-enhanced sonography perflutren lipid microspheres</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>perflutren lipid microspheres</intervention_name>
    <description>perflutren lipid microspheres IV in 0.1 cc doses, as needed, to enhance lesion conspicuity</description>
    <arm_group_label>Contrast sonography</arm_group_label>
    <other_name>Definity</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with primary hepatocellular carcinoma (HCC) or secondary (metastatic)
             carcinoma of the liver who have been referred for ultrasound-guided radiofrequency
             ablation (RFA) treatment

          -  Recent (within 90 days) CT or MRI scan with report of one or more tumors ≤ 1.5 cm in
             diameter

          -  Patient is stable and is to be managed conservatively (i.e. non-surgically)

          -  18 years of age or older

          -  Ability and willingness to provide written informed consent

        Exclusion Criteria:

          -  Known or suspected cardiac shunt(s)

          -  Known sensitivity to octafluoropropane

          -  Pregnant or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John P. McGahan, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>UC Davis School of Medicine Dept. of Radiology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UC Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 21, 2007</study_first_submitted>
  <study_first_submitted_qc>December 21, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 2, 2008</study_first_posted>
  <results_first_submitted>July 3, 2013</results_first_submitted>
  <results_first_submitted_qc>July 10, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 11, 2017</results_first_posted>
  <last_update_submitted>July 10, 2017</last_update_submitted>
  <last_update_submitted_qc>July 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>liver cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Closed to enrollment</recruitment_details>
      <pre_assignment_details>Closed to enrollment</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Contrast Sonography</title>
          <description>Contrast-enhanced sonography
perflutren lipid microspheres : IV in 0.1 cc doses, as needed, to enhance lesion conspicuity</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Contrast Sonography</title>
          <description>Contrast-enhanced sonography perflutren lipid microspheres : IV in 0.1 cc doses, as needed, to enhance lesion conspicuity</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent of Tumors With Increased Echogenicity (Brightness) Following Contrast-enhanced Sonography</title>
        <description>After the systemic iv injection of ultrasound contrast, the real time ultrasound images are visually evaluated, and small intrahepatic tumors are detected on the images. The images pre-contrast and post contrast are compared visually. One tumor per participant was analyzed.</description>
        <time_frame>15 min</time_frame>
        <population>Tumors were evaluated prior and post contrast injection, 1 tumor per participant</population>
        <group_list>
          <group group_id="O1">
            <title>Contrast Sonography</title>
            <description>Subjects undergoing contrast sonography</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Tumors With Increased Echogenicity (Brightness) Following Contrast-enhanced Sonography</title>
          <description>After the systemic iv injection of ultrasound contrast, the real time ultrasound images are visually evaluated, and small intrahepatic tumors are detected on the images. The images pre-contrast and post contrast are compared visually. One tumor per participant was analyzed.</description>
          <population>Tumors were evaluated prior and post contrast injection, 1 tumor per participant</population>
          <units>tumor</units>
          <param>Count of Units</param>
          <units_analyzed>tumor</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>tumor</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With an Increase in Echogenicity (Brightness) of Small Intrahepatic Tumors Following Contrast-enhanced Sonography Based on Tumor Type, Size, Location and Depth</title>
        <description>Visual estimation of the the effect of tumor type, size, location and depth on the conspicuity of small tumors on contrast-enhanced sonography using prior assessment or pathology for tumor type</description>
        <time_frame>15 min</time_frame>
        <population>Tumor types showed differences in enhancement</population>
        <group_list>
          <group group_id="O1">
            <title>Contrast Sonography</title>
            <description>Subjects undergoing contrast sonography</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With an Increase in Echogenicity (Brightness) of Small Intrahepatic Tumors Following Contrast-enhanced Sonography Based on Tumor Type, Size, Location and Depth</title>
          <description>Visual estimation of the the effect of tumor type, size, location and depth on the conspicuity of small tumors on contrast-enhanced sonography using prior assessment or pathology for tumor type</description>
          <population>Tumor types showed differences in enhancement</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>15 min post injection</time_frame>
      <desc>All-cause mortality and other (not including serious) adverse events were not collected/assessed</desc>
      <group_list>
        <group group_id="E1">
          <title>Contrast Sonography</title>
          <description>Contrast-enhanced sonography
perflutren lipid microspheres : IV in 0.1 cc doses, as needed, to enhance lesion conspicuity</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>John McGahan, M.D.</name_or_title>
      <organization>University of Califonia, Davis</organization>
      <phone>(916)734-0519</phone>
      <email>john.mcgahan@ucdmc.ucdavis.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

